Benzinga | May 20, 2021 08:02AM EDT

Truist Securities Upgrades Allogene Therapeutics to Buy, Raises Price Target to $41

Truist Securities analyst Asthika Goonewardene upgrades Allogene Therapeutics (NASDAQ:ALLO) from Hold to Buy and raises the price target from $34 to $41.